28 results on '"Palsdottir, Thorgerdur"'
Search Results
2. The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics—Real-world Evidence from 2018 to 2022
3. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort
4. Prostate Cancer Incidence and Mortality in Men Exposed to α1-Adrenoceptor Antagonists
5. Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
6. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
7. A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
8. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists.
9. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators
10. Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
11. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test
12. A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging
13. The Capio Prostate Cancer Center model for prostate cancer diagnostics using Stockholm3, MRI, and targeted biopsies: Real-world evidence from 2018 to 2022.
14. Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.
15. PD38-11 THE STOCKHOLM3 PROSTATE CANCER SCREENING TRIAL (STHLM3): AN INTERIM ANALYSIS OF MORTALITY RESULTS AFTER 6.5 YEARS OF FOLLOW-UP
16. PD39-02 THE CAPIO S:T GORAN MODEL FOR PROSTATE CANCER DIAGNOSIS USING STOCKHOLM3, MAGNETIC RESONANCE IMAGING AND TARGETED BIOPSIES
17. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
18. PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
19. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
20. Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test
21. Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project
22. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≥3 ng/ml
23. Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
24. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
25. Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50–69 years with PSA ≥3 ng/ml.
26. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
27. Prostate Cancer Incidence and Mortality in Men Exposed to α1-Adrenoceptor Antagonists.
28. Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.